

# Newly Diagnosed

## Treatment

## Diagnostic

## Rehabilitation

### Skin

### Salivary Gland

### Nasopharynx Only

### Oropharynx, Oral Cavity, Larynx, Hypopharynx

**ENT0061**  
[Pilot PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck \(SCCHN\)](#)

PI: Colevas  
Stanford

**ENT0070**  
[Using Mobile Health Tech to Enhance Adherence & Improve Swallowing Outcomes in H&N Cancer RT Patients](#)

PI: Starmer  
Stanford

**ENT0075**  
[Effects of Tongue Strengthening Post Partial Glossectomy](#)

PI: Kizner  
Stanford

**VAR0194** ❖  
Phase II  
Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)

PI: Divi  
Pending

**ENT0082**  
ML42362:  
Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

PI: Divi  
Stanford

**RTOG1008**  
[Phase II Adj Concurrent XRT +Chemo vs XRT Alone in Resected High-Risk Malignant Salivary Gland Tumors](#)

PI: Le  
RTOG

**NRGHN001**  
[Phase II/III Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus Deoxyribonucleic Acid](#)

PI: Le  
NRG

**ENT0072**  
Phase I d  
Limonene +Radiation +PlatinumBased Chemo for Xerostomia Prevention in LocallyAdvanced HNSCC

PI: Le  
Sponsor:  
Stanford

**NRGHN004** ❖  
[Phase II/III Radiotherapy w/ Concurrent MEDI4736 or Cetuximab in Stage III-IVB H&N Cancer](#)

PI: Beadle  
Sponsor: NRG

**NRGHN006**  
[Phase II/III Sentinel LymphNode Biopsy vs Elective Neck Dissection in Early-Stage Oral Cavity Cancer](#)


PI: Baik  
Sponsor: NRG


**NRGHN005**  
[Phase II/III De-Intensified RT in Early-Stage P16-Positive Non-Smoking Associated Oropharyngeal Cancer](#)

PI: Le  
Sponsor: NRG

### KEY


 Pending

 Open for Enrollment

 Observational Study

 Optional Path

 Trial Posting

 Enrollment on Hold

 Extension Study

 Immunotherapy